Anderson brings over 30 years of experience in research, biostatistics, and leadership to the Max board. She currently works as a Portfolio Statistics Leader at the Gates Medical Research Institute. She has contributed to several published articles, most recently RSM01, a Novel Respiratory Syncytial Virus Monoclonal Antibody: Preclinical Characterization and Results of a First-in-Human, Randomised Clinical Trial. Anderson has been a member of the American Statistical Association since 1995. During her career, she has earned several accolades, including the BMS James B.D. Palmer R&D Award for Excellence in Drug Development in 2016.